These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31113578)

  • 1. Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients.
    Uojima H; Kobayashi S; Hidaka H; Kinbara T; Fujikawa T; Nakayama T; Yamanoue H; Kanemaru T; Hashimotoh T; Hyun Sung J; Kako M; Koizumi W
    Ann Hepatol; 2019; 18(1):109-115. PubMed ID: 31113578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
    Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
    Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
    Hézode C; Asselah T; Reddy KR; Hassanein T; Berenguer M; Fleischer-Stepniewska K; Marcellin P; Hall C; Schnell G; Pilot-Matias T; Mobashery N; Redman R; Vilchez RA; Pol S
    Lancet; 2015 Jun; 385(9986):2502-9. PubMed ID: 25837829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
    Welzel TM; Asselah T; Dumas EO; Zeuzem S; Shaw D; Hazzan R; Forns X; Pilot-Matias T; Lu W; Cohen DE; Feld JJ
    Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):494-500. PubMed ID: 28416221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
    Kumada H; Chayama K; Rodrigues L; Suzuki F; Ikeda K; Toyoda H; Sato K; Karino Y; Matsuzaki Y; Kioka K; Setze C; Pilot-Matias T; Patwardhan M; Vilchez RA; Burroughs M; Redman R
    Hepatology; 2015 Oct; 62(4):1037-46. PubMed ID: 26147154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
    Ascione A; De Luca M; Melazzini M; Montilla S; Trotta MP; Petta S; Puoti M; Sangiovanni V; Messina V; Bruno S; Izzi A; Villa E; Aghemo A; Zignego AL; Orlandini A; Fontanella L; Gasbarrini A; Marzioni M; Giannini EG; Craxì A;
    Infection; 2018 Oct; 46(5):607-615. PubMed ID: 29808463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
    Lalezari J; Sullivan JG; Varunok P; Galen E; Kowdley KV; Rustgi V; Aguilar H; Felizarta F; McGovern B; King M; Polepally AR; Cohen DE
    J Hepatol; 2015 Aug; 63(2):364-9. PubMed ID: 25839406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
    Hsieh YC; Jeng WJ; Huang CH; Teng W; Chen WT; Chen YC; Lin SM; Tai DI; Lin CY; Sheen IS
    PLoS One; 2018; 13(8):e0202777. PubMed ID: 30138456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.
    Gopalakrishnan S; Khatri A; Mensing S; Redman R; Menon R; Zha J
    Adv Ther; 2016 Apr; 33(4):670-83. PubMed ID: 27084721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
    Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2018 Mar; 33(3):710-717. PubMed ID: 28762541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
    Chayama K; Notsumata K; Kurosaki M; Sato K; Rodrigues L; Setze C; Badri P; Pilot-Matias T; Vilchez RA; Kumada H
    Hepatology; 2015 May; 61(5):1523-32. PubMed ID: 25644279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
    Janczewska E; Zarębska-Michaluk D; Berak H; Piekarska A; Gietka A; Dybowska D; Mazur W; Belica-Wdowik T; Dobracki W; Tudrujek-Zdunek M; Deroń Z; Buczyńska I; Sitko M; Czauż-Andrzejuk A; Lorenc B; Białkowska-Warzecha J; Citko J; Laurans Ł; Jaroszewicz J; Socha Ł; Tronina O; Adamek B; Horban A; Halota W; Baka-Ćwierz B; Tomasiewicz K; Simon K; Garlicki A; Wawrzynowicz-Syczewska M; Flisiak R
    BMC Infect Dis; 2018 Nov; 18(1):580. PubMed ID: 30445916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
    Chan HL; Tsang OT; Hui YT; Fung J; Lui GC; Lai CL; Wong GL; Chan KH; But DY; Lai MS; Lao WC; Chan CK; Lam YS; Seto WK; Li C; Yuen MF; Wong VW
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1230-1233. PubMed ID: 27869328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
    Schnell G; Tripathi R; Krishnan P; Beyer J; Reisch T; Irvin M; Dekhtyar T; Setze C; Rodrigues L; Alves K; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
    J Med Virol; 2018 Jan; 90(1):109-119. PubMed ID: 28842997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection.
    Ahmed M; Mansey AE; Wahsh EA; Gomaa AA; Rabea HM
    Curr Med Sci; 2021 Jun; 41(3):581-586. PubMed ID: 34047942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
    Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
    Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
    Asselah T; Hézode C; Qaqish RB; ElKhashab M; Hassanein T; Papatheodoridis G; Feld JJ; Moreno C; Zeuzem S; Ferenci P; Yu Y; Redman R; Pilot-Matias T; Mobashery N
    Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):25-35. PubMed ID: 28404108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
    Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
    Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
    Sato K; Chayama K; Alves K; Toyoda H; Suzuki F; Kato K; Rodrigues L; Zhang X; Setze C; Pilot-Matias T; Burroughs M; Redman R; Kumada H
    Adv Ther; 2017 Jun; 34(6):1449-1465. PubMed ID: 28536999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
    Feld JJ; Moreno C; Trinh R; Tam E; Bourgeois S; Horsmans Y; Elkhashab M; Bernstein DE; Younes Z; Reindollar RW; Larsen L; Fu B; Howieson K; Polepally AR; Pangerl A; Shulman NS; Poordad F
    J Hepatol; 2016 Feb; 64(2):301-307. PubMed ID: 26476290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.